⌘K
Loading ticker…
CG Oncology, Inc. Common stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, CG Oncology, Inc. Common stock (CGON) has a 3-month relative strength percentile of 54 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 72. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.0%, relative volume 4.67×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
54 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
CGON is in a stage 2 uptrend, week 1. Currently in a 30-day base; basing ADR 5.6% (broad 4.8%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 11.4% / 36.3%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
CGON is held by 8 ETFs as of Mar 2026. Top owner: VTI at 0.01% weight, $149M notional. Top 3 carry $353M.
Top 8 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.01% | $149M |
| VBVanguard Small Cap ETF | 0.07% | $107M |
| IWMiShares Russell 2000 ETF | 0.14% | $98M |
| XBIState Street SPDR S&P Biotech ETF | 1.16% | $86M |
| VBRVanguard Small Cap Value ETF | 0.11% | $68M |
| VXFVanguard Extended Market ETF | 0.06% | $52M |
| IWOiShares Russell 2000 Growth ETF | 0.27% | $33M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.01% | $6M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CGON Jan avg: 10.15% median: 4.85% win: 100% σ: 13.37% n: 3 2024-01-26 → 2026-05-29 | CGON Feb avg: 6.32% median: 12.97% win: 67% σ: 17.95% n: 3 2024-01-26 → 2026-05-29 | CGON Mar avg: 2.66% median: -1.81% win: 33% σ: 10.91% n: 3 2024-01-26 → 2026-05-29 | CGON Apr avg: 0.06% median: -1.39% win: 33% σ: 9.31% n: 3 2024-01-26 → 2026-05-29 | CGON May avg: -10.17% median: -6.67% win: 0% σ: 7.64% n: 3 2024-01-26 → 2026-05-29 | CGON Jun avg: -0.81% median: -0.81% win: 50% σ: 3.24% n: 2 2024-01-26 → 2026-05-29 (current) | CGON Jul avg: 4.15% median: 4.15% win: 100% σ: 2.11% n: 2 2024-01-26 → 2026-05-29 | CGON Aug avg: 5.54% median: 5.54% win: 100% σ: 7.14% n: 2 2024-01-26 → 2026-05-29 | CGON Sep avg: 26.25% median: 26.25% win: 100% σ: 33.86% n: 2 2024-01-26 → 2026-05-29 | CGON Oct avg: 0.80% median: 0.80% win: 50% σ: 9.37% n: 2 2024-01-26 → 2026-05-29 | CGON Nov avg: 0.72% median: 0.72% win: 50% σ: 4.12% n: 2 2024-01-26 → 2026-05-29 | CGON Dec avg: -12.44% median: -12.44% win: 0% σ: 7.12% n: 2 2024-01-26 → 2026-05-29 |